Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic conditions, today announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has provided scientific advice supporting the company's submission of an Investigational Medicinal...
2025-06-25 9:00 AM EDT
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
San Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate in a high-profile clinical panel discussion at the United Mitochondrial Disease Foundation's ("UMDF") 2025...
2025-06-20 9:00 AM EDT
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation of its French clinical site for Thiogenesis' ongoing Phase 2 clinical trial evaluating TTI-0102 in patients with Mitochondrial Encephalomyopathy with Lactic Acidosis and...
2025-06-17 9:00 AM EDT
Thiogenesis Announces Grant of Stock Options
San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to the terms of the Company's Omnibus Equity Incentive Plan, on June 11, 2025, the Company's board of directors approved a total grant of 400,000 common...
2025-06-12 10:01 AM EDT
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing disulfides that drive the production of intracellular cysteine, an amino acid that is a critical precursor to the generation of the master antioxidant glutathione and other important therapeutic compounds, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the...
2025-06-11 9:00 AM EDT
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
San Diego, California--(Newsfile Corp. - May 14, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has dosed its first two patients in its Phase 2 clinical trial of TTI-0102, Thiogenesis' lead product candidate for the potential treatment of the...
2025-05-14 9:00 AM EDT
Thiogenesis Announces European Consulting and Investor Relations Agreement
San Diego, California--(Newsfile Corp. - February 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has entered into a consulting and investor relations agreement effective February 15, 2025 (the "Agreement") with Bull Markets Media GmbH (the...
2025-02-20 9:00 AM EST
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
San Diego, California--(Newsfile Corp. - February 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF. The OTCQX Best Market is the highest-level market of OTC...
2025-02-12 9:00 AM EST
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
San Diego, California--(Newsfile Corp. - January 27, 2025) - Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part II - National and Patient Level Documentation, for Thiogenesis'...
2025-01-27 9:00 AM EST
Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease
San Diego, California--(Newsfile Corp. - December 10, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine, that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions is pleased to announce that Patrice Rioux, MD, Ph.D., Thiogenesis' Chief Executive Officer, presented an update on the...
2024-12-10 9:00 AM EST
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, that includes precursors to cysteamine and that have potent antioxidant and anti-inflammatory properties for the treatment of inherited mitochondrial diseases and metabolic conditions, is pleased to announce that it has attained Depository Trust Company ("DTC")...
2024-11-28 9:00 AM EST
Thiogenesis Announces Important Core Patent Allowed in Europe
San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related metabolic conditions; is pleased to announce that one of its core patents titled, "Methods For The Treatment of Cysteamine Sensitive Disorders," has...
2024-11-04 9:00 AM EST
Thiogenesis Announces Investor Relations Engagement
San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active compounds that have strong antioxidant and anti-inflammatory properties and that have the potential to treat mitochondrial diseases, including metabolic syndrome, today announced that it has entered into an investor relations agreement (the IR Agreement), effective October 1, 2024, with Triomphe...
2024-09-27 10:00 AM EDT
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium
San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., Ph.D., the Company's Chief Executive Officer, has been invited to present this week at the Cure Mito Foundation's "Empower and Inspire: 3rd Annual...
2024-09-17 9:30 AM EDT
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program
San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collaborative Agreement with the University of California San Diego ("UCSD"). Thiogenesis will work with Jeffrey Schwimmer, M.D., as the Principal...
2024-08-20 9:00 AM EDT
Thiogenesis Announces Leigh Syndrome Clinical Program
San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Master Research Agreement with a leading U.S. pediatric hospital. In the agreement, the pediatric hospital will act as the Investigator in assessing...
2024-07-18 9:00 AM EDT
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound...
2024-03-25 9:00 AM EDT
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement, originally announced on November 20, 2023 (the "Offering"). Under this second tranche, the Company has issued 417,000 common shares for gross proceeds of C$312,750. The Company paid cash...
2023-12-20 9:00 AM EST
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation
San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that it has closed a non-brokered private placement (the "Offering") through the issuance of 5,584,167 common shares (the "Offered Shares") for gross proceeds of $4,188,125. In connection with closing, the Company paid aggregate cash finder's fees of $285,294 and issued an...
2023-12-18 12:00 PM EST
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing compounds for unmet pediatric diseases, announced today that its CEO, Dr. Patrice Rioux, has been invited to lead a roundtable discussion on redox signaling at the 6th Annual Mitochondria Symposium at UCLA, in Los Angeles, California, on December 8, 2023. Reactive oxygen species...
2023-12-04 9:00 AM EST